FDA Pipeline: New Priority Reviews, Designations, and Clearances, Plus Statements on Genetic Testing and Class Labeling
December 11, 2018 - The FDA accepted a supplemental biologics license application (sBLA) and granted Priority Review for atezolizumab in combination with carboplatin and etoposide for the first-line treatment of patients with extensive-stage small cell lung cancer (SCLC). ...Leggi tutto